Krensavage Asset Management, LLC — 13F Holdings & Portfolio
CIK 1609251 · latest 13F-HR filed 2026-05-15
Krensavage Asset Management, LLC manages $255.7K in 13F-reported U.S. long-equity assets across 20 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are UTHR (19.55%), ENTA (14.16%), JAZZ (12.41%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 5 new positions, exited 3, added to 6, and trimmed 5.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$255.7K
Long-equity book
20
Distinct positions
2026-03-31
Filed 2026-05-15
+5 / −3 / ↑6 / ↓5
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- UNITED THERAPEUTICS CORP$5.5K +12.4%
- ULTRAGENYX PHARMACEUTICAL IN$4.7K +137.9%
- JAZZ PHARMACEUTICALS PLC$3.2K +11.2%
- BIOGEN INC$1.9K +108.4%
- ALKERMES PLC$796 +26.4%
Top Trims
- ENANTA PHARMACEUTICALS INC-$7.4K -17.0%
- BIONTECH SE-ADR-$4.2K -44.2%
- EXELIXIS INC-$3.8K -17.6%
- VANDA PHARMACEUTICALS INC-$2.3K -21.7%
- SUPERNUS PHARMACEUTICALS INC-$1.1K -6.9%
New Positions
- INDIVIOR PHARMACEUTICALS INC$10.3K
- EMBECTA CORP$6.5K
- ARDELYX INC$3.0K
- INMODE LTD$1.7K
- ABBOTT LABORATORIES$513
Exited Positions
- AVADEL PHARMACEUTICALS$18.4K
- CARDINAL HEALTH INC$15.2K
- INDIVIOR PLC$12.2K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | UNITED THERAPEUTICS CORP | UTHR | 91307C102 | $50.0K | 19.55% | 84,282 | SH |
| 2 | ENANTA PHARMACEUTICALS INC | ENTA | 29251M106 | $36.2K | 14.16% | 2,866,138 | SH |
| 3 | JAZZ PHARMACEUTICALS PLC | JAZZ | G50871105 | $31.7K | 12.41% | 167,816 | SH |
| 4 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $29.6K | 11.59% | 524,786 | SH |
| 5 | EXELIXIS INC | EXEL | 30161Q104 | $17.8K | 6.97% | 415,693 | SH |
| 6 | SANOFI-ADR | SNY | 80105N105 | $15.6K | 6.10% | 323,946 | SH |
| 7 | SUPERNUS PHARMACEUTICALS INC | SUPN | 868459108 | $14.5K | 5.67% | 280,681 | SH |
| 8 | INDIVIOR PHARMACEUTICALS INC | INDV | 45579U109 | $10.3K | 4.05% | 339,532 | SH |
| 9 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $8.2K | 3.20% | 390,879 | SH |
| 10 | VANDA PHARMACEUTICALS INC | VNDA | 921659108 | $8.2K | 3.19% | 1,180,388 | SH |
| 11 | EMBECTA CORP | EMBC | 29082K105 | $6.5K | 2.54% | 735,340 | SH |
| 12 | GSK PLC-SPON ADR | GSK | 37733W204 | $5.3K | 2.09% | 96,729 | SH |
| 13 | BIONTECH SE-ADR | BNTX | 09075V102 | $5.3K | 2.07% | 59,523 | SH |
| 14 | ALKERMES PLC | ALKS | G01767105 | $3.8K | 1.49% | 107,822 | SH |
| 15 | BIOGEN INC | BIIB | 09062X103 | $3.7K | 1.43% | 20,000 | SH |
| 16 | REGENERON PHARMACEUTICALS | REGN | 75886F107 | $3.1K | 1.21% | 4,000 | SH |
| 17 | ARDELYX INC | ARDX | 039697107 | $3.0K | 1.17% | 500,000 | SH |
| 18 | INMODE LTD | INMD | M5425M103 | $1.7K | 0.65% | 120,942 | SH |
| 19 | EVOLUS INC | EOLS | 30052C107 | $649 | 0.25% | 157,985 | SH |
| 20 | ABBOTT LABORATORIES | ABT | 002824100 | $513 | 0.20% | 5,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $255.7K | 20 | 0001609251-26-000004 |
| 2025-12-31 | 2026-02-18 | $283.1K | 18 | 0001609251-26-000003 |
| 2025-09-30 | 2025-11-17 | $234.7K | 17 | 0001609251-25-000007 |